Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
0.00490… dead.
0.004720 Broke bitches!
Enablers are screwed. 0.004’s are printing. 0.0007 is on deck.
You’re delusional.
0.004’s printing
So says the broke imbecile.
When 0.00085 of a penny changes the value of your investment by 17%, you know you’re screwed.
Delusional.
$2M market cap shows Brilacidin’s value has already been reduced to $0.
You yourself said ur f’d.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172594202
Good morning enablers. Friendly reminder…. 0.0050. Bag holders are screwed. IPIX IS DEAD. You, yes you, are SCREWED.
Good morning enablers. Friendly reminder…. Bag holders are screwed. IPIX IS DEAD. You, yes you, are SCREWED.
Good morning enablers. Friendly reminder…. Bag holders are screwed. IPIX IS DEAD. You, yes you, are SCREWED.
Thanks man! Scoop up those cheapies! Only going down from here!
BeaMed is ur dangling cannoli
IPIX is dead.
Who cares! They could own shares equivalent to 50 dinners at this point. Whoopty fuckin’ doo.
That’s the reality of the situation.
The CEO surrendered his shares.
From the most recent 10Q:
Surrender of Shares
On December 29, 2022, Mr. Ehrlich entered into a Share Surrender Agreement with the Company pursuant to which Mr. Ehrlich permanently surrendered all legal right, title, and interest in 11,307,527 shares of Class B common stock to the Company and relinquished all rights in such shares, free and clear of any liens, mortgages, adverse claims, charges, security interests, encumbrances, any interest of any third party, or other restrictions or limitations whatsoever of any kind. Mr. Ehrlich received no consideration from the Company or any other party in connection with the surrender. Mr. Ehrlich effected the Surrender solely for his individual tax planning purposes. These 11,307,527 shares of Class B common stock were retired and returned to Class B common stock on the same day.
From the most recent 10Q:
For the three months ended September 30, 2023, the Company had a net loss of $0.9 million and negative cash flow from operations of $0.7 million. As of September 30, 2023, the Company has negative working capital of $4.1 million. As of September 30, 2023, the Company’s cash amounted to $0.9 million and current liabilities amounted to $5.0 million. The Company has expended substantial funds on its clinical trials and expects to continue our spending on research and development expenditures, subject to having adequate available funding. We expect to incur further losses in the development of our business and have been dependent on funding operations from inception. These conditions raise substantial doubt about our ability to continue as a going concern.
————-
As a result of the assessment of the Company’s internal control over financial reporting as of June 30, 2023, management concluded that the Company’s accounting procedures relevant to an unconsolidated foreign investment are not sufficiently formal that management can determine whether the applicable control objectives are met and adequate documentation supporting the procedures is in place. Specifically, the Company does not have sufficient controls to conclude that data from the unconsolidated foreign investee underlying the Company’s financial statements is captured completely, accurately and timely, in accordance with the Company’s policies and procedures. This material weakness could result in a misstatement of the recorded equity investment as well as the equity in loss from equity investment that would not be prevented or detected on a timely basis.
————
The Company recently learned that Alfasigma is considering terminating further work under the License Agreement, although as of the date of this report, Alfasigma has not notified the Company of the termination of the License Agreement or a cessation of further work under the License Agreement.
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products.
We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA.
Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Here we are talking about 100k shares being worth dinner when it was once worth upwards of $1/2 Million.
Shareholders who say IPIX isn’t dead need to wake the hell up and face the fact their investment is gone forever.
0.004 down the sewer it goes.
Perspective - one could buy a nice family dinner for 100,000 shares.
No argument. The company is dead. End of story.
The value is the value and it’s essentially zero. Nothing’s changing. IPIX is dead.
Dunning-Kruger effect.
Assessment - Zero. $0 = broke bitch
The CEO however has all the $.
Who’s the dumb cuck?
Even a fool is thought wise if he keeps silent, and discerning if he holds his tongue.
Even a fool, when he holdeth his peace, is counted wise: and he that shutteth his lips is esteemed a man of understanding.
Then came Honest Abe.
Est. IQ below 70. Yes - a repeat.
%’s screw w/ me too. 100,000 shares hasn’t been worth the price of dinner this week. At one point it was worth $70. Soon to be worth much less.
Ur an idiot. IPIX is dead.
0.0007 LMFAO
It must be dangerous to be a jive turkey this close to Thanksgiving!
That’s one way to swallow it.
Sometimes it’s best to leave the Cannolis. IPIX sleeps with the fishes.
Hahahaha